N-heterocyclic sulfonamides having endothelin receptor activity
US5668137A · kind A · utility
22Cited by
5References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 20, 1996 |
| Grant date | Sep 16, 1997 |
| Priority date | — |
| Expiry date | Jun 20, 2016 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D261/16
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention concerns pharmaceutically useful compounds of the formula I, in which R.sup.1, R.sup.2, R.sup.3, n, m and Het have any of the meanings defined herein, and their pharmaceutically-acceptable salts, and pharmaceutical compositions containing them. The novel compounds possess endothelin receptor antagonist activity and are useful, for example, in the treatment of diseases or medical conditions in which elevated or abnormal levels of endothelin play a significant causative role. The invention further concerns processess for the manufacture of the novel compounds and the use of the compounds in medical treatment.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.